<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04627740</url>
  </required_header>
  <id_info>
    <org_study_id>TCRCureALPPCART</org_study_id>
    <nct_id>NCT04627740</nct_id>
  </id_info>
  <brief_title>Anti-ALPP CAR-T Cells Immunotherapy for Ovarian and Endometrial Cancer</brief_title>
  <official_title>A Single-Arm, Single-Center, Open-Label Pilot Study of Anti-ALPP CART-cells in Patient With Alkaline Phosphatase, Placental (ALPP)-Positive Metastatic Ovarian and Endometrial Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TCRCure Biopharma Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xinqiao Hospital of Chongqing</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial is to evaluate the safety and efficacy of anti-ALPP chimeric&#xD;
      antigen receptor (CAR)-modified T (CAR-T) cells in treating patients with ALPP-positive&#xD;
      metastatic ovarian and endometrial cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
      To evaluate the number of ALPP-positive participants with treatment-related adverse events as&#xD;
      assessed by CTCAE v4.0 after infusion with anti-ALPP CAR-T cells.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      The number of patients experience objective response from anti-ALPP CAR-T cells treatment&#xD;
&#xD;
      To evaluate the progression-free survival (PFS) of anti-ALPP CAR-T cells in patients with&#xD;
      ALPP-positive patients.&#xD;
&#xD;
      The number and percent of ALPP-CART cells in peripheral blood from ALPP-positive patients at&#xD;
      6 months after infusion&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients suffering treatment-related AE</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the number of ALPP-positive participants with treatment-related adverse events as assessed by CTCAE v4.0 after infusion with anti-ALPP CAR-T cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate to ALPP-CART infusion</measure>
    <time_frame>Eight weeks</time_frame>
    <description>The number of patients experience objective response from anti-ALPP CAR-T cells treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival to ALPP-CART infusion</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate the progression-free survival (PFS) of anti-ALPP CAR-T cells in patients with mesothelin-positive advanced ovarian carcinoma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of peripheral CAR-T after infusion</measure>
    <time_frame>6 months</time_frame>
    <description>The number of ALPP-CART cells in peripheral blood from ALPP-positive patients at 6 months after infusion</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>CART treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclophosphamide will be administered at dose of 20mg/kg for 1 day and then fludarabine will be given for the next 3 days with 35mg/m2 and then the CAR-T cells will be administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Retroviral vector-transduced autologous T cells to express anti-ALPP CARs</intervention_name>
    <description>Cyclophosphamide will be administered at dose of 20mg/kg for 1 day and then fludarabine will be given for the next 3 days with 35mg/m2 and then the CAR-T cells will be administered</description>
    <arm_group_label>CART treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Expected to survive more than 3 months&#xD;
&#xD;
          -  PS 0-2&#xD;
&#xD;
          -  Immunohistochemistry was confirmed to be mesothelin positive ALPP (higher than 50%)&#xD;
&#xD;
          -  Patients with no curative regimen to receive&#xD;
&#xD;
          -  WBC&gt;3.5×1e+9/L,Hb&gt;90g/L,PLT&gt;75×1e+9/L&#xD;
&#xD;
          -  HBV DNA copy number less than 100/ml&#xD;
&#xD;
          -  ALT≤5ULN, AST≤5ULN, TB≤1.5ULN, ALB≥35g/L&#xD;
&#xD;
          -  Understand this test and have signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Autoimmune diseases, or any uncontrolled active disease that hinders participation in&#xD;
             the trial&#xD;
&#xD;
          -  Decompensated liver cirrhosis, liver function Child-pugh C grade&#xD;
&#xD;
          -  Portal vein tumor thrombus, arterial portal fistula, hepatic arteriovenous&#xD;
&#xD;
          -  Long-term use of immunosuppressive agents after organ transplantation&#xD;
&#xD;
          -  Screening indicated that the target cell transfection rate was less than 30%&#xD;
&#xD;
          -  Invasive pulmonary embolism, deep venous thrombosis, or other major arterial / venous&#xD;
             thromboembolic events occurred 30 days or 30 days prior to randomization&#xD;
&#xD;
          -  Subjects had an active or uncontrollable infection requiring systemic therapy 14 days&#xD;
             or 14 days prior to randomization&#xD;
&#xD;
          -  Pregnant or lactating subjects&#xD;
&#xD;
          -  In the opinion of the investigator, the presence of a medical history or a history of&#xD;
             mental state may increase the number of subjects associated with the risk factors&#xD;
             associated with the study or study drug administration&#xD;
&#xD;
          -  Subjects who have signed a written consent or who are in compliance with the study&#xD;
             procedure; or who are unwilling or unable to comply with the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>November 11, 2020</last_update_submitted>
  <last_update_submitted_qc>November 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xinqiao Hospital of Chongqing</investigator_affiliation>
    <investigator_full_name>Qingzhu Jia, M.D.</investigator_full_name>
    <investigator_title>Secretary</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

